文献速递临床试验与 GCP

多塞平漱口水或苯海拉明-利多卡因-抗酸剂漱口水与安慰剂对放疗相关口腔黏膜炎疼痛的影响:Alliance A221304随机临床试验

Effect of Doxepin Mouthwash or Diphenhydramine-Lidocaine-Antacid Mouthwash vs Placebo on Radiotherapy-Related Oral Mucositis Pain: The Alliance A221304 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01

这项3期随机试验在30家美国机构纳入275例接受根治性头颈部放疗且口腔黏膜炎疼痛评分≥4分的患者,比较多塞平漱口水、苯海拉明-利多卡因-抗酸剂漱口水与安慰剂单次给药后4小时内疼痛缓解。两种漱口水较安慰剂均显著降低疼痛,但效应量小于最小临床重要差异3.5分。

要点

  • 多塞平漱口水较安慰剂降低疼痛2.9分(95%CI 0.2-6.0;P=.02),差异有统计学意义但小于最小临床重要差异3.5分。
  • 苯海拉明-利多卡因-抗酸剂漱口水较安慰剂降低疼痛3.0分(95%CI 0.1-5.9;P=.004),差异有统计学意义但小于最小临床重要差异3.5分。
  • 多塞平漱口水较安慰剂报告更多嗜睡(1.5分,95%CI 0-4.0;P=.03)、异味(1.5分,95%CI 0-3.0;P=.002)和刺痛或烧灼感(4.0分,95%CI 2.5-5.0;P<.001)。

核心结论

  • 在接受头颈部放疗的患者中,多塞平漱口水或苯海拉明-利多卡因-抗酸剂漱口水较安慰剂显著降低给药后4小时内的口腔黏膜炎疼痛,但效应量小于最小临床重要差异。
  • 需要进一步研究评估两种漱口水的长期疗效和安全性。

研究设计与样本

  • 3期随机临床试验,2014年11月1日至2016年5月16日在30家美国机构开展,纳入275例接受根治性头颈部放疗且口腔黏膜炎疼痛评分≥4分(量表0-10分)的患者。
  • 92例随机分配至多塞平漱口水(25 mg/5 mL水),91例至苯海拉明-利多卡因-抗酸剂漱口水,92例至安慰剂,随访最长28天。
  • 主要终点为单次给药后4小时内口腔黏膜炎总疼痛缓解(以曲线下面积定义并校正基线疼痛评分),最小临床重要差异为3.5分。

主要发现

  • 275例随机患者中位年龄61岁,58例(21%)为女性,227例(83%)按方案完成治疗。
  • 给药后4小时内黏膜炎疼痛:多塞平漱口水组降低11.6分,苯海拉明-利多卡因-抗酸剂漱口水组降低11.7分,安慰剂组降低8.7分。
  • 多塞平漱口水较安慰剂组间差异2.9分(95%CI 0.2-6.0;P=.02),苯海拉明-利多卡因-抗酸剂漱口水较安慰剂组间差异3.0分(95%CI 0.1-5.9;P=.004)。
  • 多塞平漱口水较安慰剂报告更多嗜睡(1.5分,95%CI 0-4.0;P=.03)、异味(1.5分,95%CI 0-3.0;P=.002)和刺痛或烧灼感(4.0分,95%CI 2.5-5.0;P<.001)。
  • 最大3级不良事件:多塞平漱口水组3例(4%),苯海拉明-利多卡因-抗酸剂漱口水组3例(4%),安慰剂组2例(2%);疲乏在多塞平漱口水组报告5例(6%),苯海拉明-利多卡因-抗酸剂漱口水组无患者报告。

关键数值与推荐

  • 疼痛评分量表0(最好)至10(最差),入组要求口腔黏膜炎疼痛评分≥4分。
  • 主要终点最小临床重要差异为3.5分。
  • 多塞平漱口水剂量为25 mg/5 mL水。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步研究评估两种漱口水的长期疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Oral mucositis causes substantial morbidity during head and neck radiotherapy. In a randomized study, doxepin mouthwash was shown to reduce oral mucositis-related pain. A common mouthwash comprising diphenhydramine-lidocaine-antacid is also widely used. OBJECTIVE: To evaluate the effect of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash for the treatment of oral mucositis-related pain. DESIGN, SETTING, AND PARTICIPANTS: A phase 3 randomized trial was conducted from November 1, 2014, to May 16, 2016, at 30 US institutions and included 275 patients who underwent definitive head and neck radiotherapy, had an oral mucositis pain score of 4 points or greater (scale, 0-10), and were followed up for a maximum of 28 days. INTERVENTIONS: Ninety-two patients were randomized to doxepin mouthwash (25 mg/5 mL water); 91 patients to diphenhydramine-lidocaine-antacid; and 92 patients to placebo. MAIN OUTCOME AND MEASURES: The primary end point was total oral mucositis pain reduction (defined by the area under the curve and adjusted for baseline pain score) during the 4 hours after a single dose of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash compared with a single dose of placebo. The minimal clinically important difference was a 3.5-point change. The secondary end points included drowsiness, unpleasant taste, and stinging or burning. All scales ranged from 0 (best) to 10 (worst). RESULTS: Among the 275 patients randomized (median age, 61 years; 58 [21%] women), 227 (83%) completed treatment per protocol. Mucositis pain during the first 4 hours decreased by 11.6 points in the doxepin mouthwash group, by 11.7 points in the diphenhydramine-lidocaine-antacid mouthwash group, and by 8.7 points in the placebo group. The between-group difference was 2.9 points (95% CI, 0.2-6.0; P = .02) for doxepin mouthwash vs placebo and 3.0 points (95% CI, 0.1-5.9; P = .004) for diphenhydramine-lidocaine-antacid mouthwash vs placebo. More drowsiness was reported with doxepin mouthwash vs placebo (by 1.5 points [95% CI, 0-4.0]; P = .03), unpleasant taste (by 1.5 points [95% CI, 0-3.0]; P = .002), and stinging or burning (by 4.0 points [95% CI, 2.5-5.0]; P < .001). Maximum grade 3 adverse events for the doxepin mouthwash occurred in 3 patients (4%); diphenhydramine-lidocaine-antacid mouthwash, 3 (4%); and placebo, 2 (2%). Fatigue was reported by 5 patients (6%) in the doxepin mouthwash group and no patients in the diphenhydramine-lidocaine-antacid mouthwash group. CONCLUSIONS AND RELEVANCE: Among patients undergoing head and neck radiotherapy, the use of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash vs placebo significantly reduced oral mucositis pain during the first 4 hours after administration; however, the effect size was less than the minimal clinically important difference. Further research is needed to assess longer-term efficacy and safety for both mouthwashes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02229539.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Sio TT, Le-Rademacher JG, Leenstra JL, et al. Effect of Doxepin Mouthwash or Diphenhydramine-Lidocaine-Antacid Mouthwash vs Placebo on Radiotherapy-Related Oral Mucositis Pain: The Alliance A221304 Randomized Clinical Trial. JAMA. 2019. PMID: 30990550. doi:10.1001/jama.2019.3504

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。